US clinical hold over Allogene’s entire pipeline has just been lifted.
Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.